Stock comparison
LeMaitre Vascular
Vertex Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
VRTX
Vertex Pharmaceuticals
Market cap
$110.28B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | VRTX | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 64C | LMAT |
| Benjamin Graham | 89A | 66D | LMAT |
| Philip Fisher |
Side-by-side metrics
| Metric | LMAT | VRTX |
|---|---|---|
| Market cap | $2.23B | $110.28B |
| P/E (TTM) | 37.1x | 25.6x |
| EV/EBIT | 36.6x | 22.6x |
| ROIC (TTM) | 9.43% | 17.74% |
| Gross margin | 72.39% | 86.28% |
| Net margin | 24.35% | 35.4% |
| Revenue CAGR 5y | 12.75% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EPS CAGR 5y19.04%vs 14.2%+25%
VRTX leads on
- Market cap$110.28Bvs $2.23B+98%
More like VRTX
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.